Cargando…
Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action hav...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225101/ https://www.ncbi.nlm.nih.gov/pubmed/35743749 http://dx.doi.org/10.3390/jpm12060964 |
_version_ | 1784733536818823168 |
---|---|
author | Braunstein, Zachary Ruiz, Miguel Hanel, Walter Shindiapina, Polina Reneau, John C. Brammer, Jonathan E. |
author_facet | Braunstein, Zachary Ruiz, Miguel Hanel, Walter Shindiapina, Polina Reneau, John C. Brammer, Jonathan E. |
author_sort | Braunstein, Zachary |
collection | PubMed |
description | Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action have been evaluated for relapsed and refractory PTCLs. In this review, we explore the current standard of care for relapsed/refractory PTCL, and evaluate in depth novel and emerging therapies, their scientific basis, and current trials for relapsed/refractory PTCL. |
format | Online Article Text |
id | pubmed-9225101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92251012022-06-24 Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas Braunstein, Zachary Ruiz, Miguel Hanel, Walter Shindiapina, Polina Reneau, John C. Brammer, Jonathan E. J Pers Med Review Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action have been evaluated for relapsed and refractory PTCLs. In this review, we explore the current standard of care for relapsed/refractory PTCL, and evaluate in depth novel and emerging therapies, their scientific basis, and current trials for relapsed/refractory PTCL. MDPI 2022-06-13 /pmc/articles/PMC9225101/ /pubmed/35743749 http://dx.doi.org/10.3390/jpm12060964 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Braunstein, Zachary Ruiz, Miguel Hanel, Walter Shindiapina, Polina Reneau, John C. Brammer, Jonathan E. Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas |
title | Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas |
title_full | Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas |
title_fullStr | Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas |
title_full_unstemmed | Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas |
title_short | Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas |
title_sort | recent advances in the management of relapsed and refractory peripheral t-cell lymphomas |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225101/ https://www.ncbi.nlm.nih.gov/pubmed/35743749 http://dx.doi.org/10.3390/jpm12060964 |
work_keys_str_mv | AT braunsteinzachary recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas AT ruizmiguel recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas AT hanelwalter recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas AT shindiapinapolina recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas AT reneaujohnc recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas AT brammerjonathane recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas |